These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17498552)

  • 21. A dual colour dual fusion fluorescence in situ hybridisation study on the genesis of complex variant translocations in chronic myelogenous leukaemia.
    So CC; Wan TS; Yip SF; Chan LC
    Oncol Rep; 2008 May; 19(5):1181-4. PubMed ID: 18425374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The clinical significance of interphase fluorescence in situ hybridization monitoring chimeric status after sex-mismatched allogeneic hematopoietic stem cell transplantation for leukemia].
    Liu Q; Song L; Zhang Y; Wei Y; Xu D; Sun J; Liu X; Xu B; Meng F; Zhou S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Apr; 22(2):212-5. PubMed ID: 15793790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The detection and significance of minimal residual disease in chronic myeloid leukemia.
    Radich JP
    Medicina (B Aires); 2000; 60 Suppl 2():66-70. PubMed ID: 11188935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel tricolor, dual-fusion fluorescence in situ hybridization method to detect BCR/ABL fusion in cells with t(9;22)(q34;q11.2) associated with deletion of DNA on the derivative chromosome 9 in chronic myelocytic leukemia.
    Smoley SA; Brockman SR; Paternoster SF; Meyer RG; Dewald GW
    Cancer Genet Cytogenet; 2004 Jan; 148(1):1-6. PubMed ID: 14697634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Using real-time polymerase chain reaction to quantitate bcr-abl mRNA].
    Liu JX; Liu JL; Wang GJ
    Ai Zheng; 2006 Nov; 25(11):1447-9. PubMed ID: 17094919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Molecular genetics in chronic myeloid leukemia with variant Ph translocation].
    Wu W; Li JY; Zhu Y; Qiu HR; Pan JL; Xu W; Chen LJ; Shen YF; Xue YQ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):470-3. PubMed ID: 17680547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
    Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
    Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter investigation with D-FISH BCR/ABL1 probes.
    Dewald G; Stallard R; Alsaadi A; Arnold S; Blough R; Ceperich TM; Rafael Elejalde B; Fink J; Higgins JV; Higgins RR; Hoeltge GA; Hsu WT; Johnson EB; Kronberger D; McCorquodale DJ; Meisner LF; Micale MA; Oseth L; Payne JS; Schwartz S; Sheldon S; Sophian A; Storto P; Van Tuinen P; Wenger GD; Wiktor A; Willis LA; Yung JF; Zenger-Hain J
    Cancer Genet Cytogenet; 2000 Jan; 116(2):97-104. PubMed ID: 10640140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Detection of abnormal numbers of chromosome 8 with interphase fluorescence in situ hybridization in hematologic malignancies].
    Wang HP; Li GX; Qiao ZH; Wang HW
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Aug; 21(4):395-7. PubMed ID: 15300644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
    Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Detection of BCR/ABL Fusion Gene and ASS1 Gene Deletion by Using Tricolor Dual-fusion Probe].
    Zhang ZH; Wang YF; Wang M; Dong F; Wan W; Ke XY; Jing HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1115-1122. PubMed ID: 32798385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia.
    Thörn I; Olsson-Strömberg U; Ohlsen C; Jonsson AM; Klangby U; Simonsson B; Barbany G
    Haematologica; 2005 Nov; 90(11):1471-6. PubMed ID: 16266893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
    Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined analysis of morphology and fluorescence in situ hybridization in follow-up of minimal residual disease in a child with Philadelphia-positive acute lymphoblastic leukemia.
    Bielorai B; Golan H; Trakhtenbrot L; Reichart M; Toren A; Daniely M; Zilberstein Y; Amariglio N; Rechavi G; Kaplinsky C
    Cancer Genet Cytogenet; 2002 Oct; 138(1):64-8. PubMed ID: 12419587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a D-FISH method to detect DEK/CAN fusion resulting from t(6;9)(p23;q34) in patients with acute myelogenous leukemia.
    Shearer BM; Knudson RA; Flynn HC; Ketterling RP
    Leukemia; 2005 Jan; 19(1):126-31. PubMed ID: 15510206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
    Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
    Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Standardization criteria for the detection of BCR/ABL fusion in interphase nuclei of chronic myelogenous leukemia patients by fluorescence in situ hybridization.
    Cohen N; Novikov I; Hardan I; Esa A; Brok-Simoni F; Amariglio N; Rechavi G; Ben-Bassat I; Trakhtenbrot L
    Cancer Genet Cytogenet; 2000 Dec; 123(2):102-8. PubMed ID: 11150599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimal residual disease testing of acute leukemia by flow cytometry immunophenotyping: a retrospective comparison of detection rates with flow cytometry DNA ploidy or FISH-based methods.
    Zwick D; Cooley L; Hetherington M
    Lab Hematol; 2006; 12(2):75-81. PubMed ID: 16751134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
    Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
    Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysis.
    Shimoni A; Nagler A; Kaplinsky C; Reichart M; Avigdor A; Hardan I; Yeshurun M; Daniely M; Zilberstein Y; Amariglio N; Brok-Simoni F; Rechavi G; Trakhtenbrot L
    Leukemia; 2002 Aug; 16(8):1413-8; discussion 1419-22. PubMed ID: 12145678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.